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The role of the human microbiome in schizophrenia remains largely unexplored.
The microbiome has been shown to alter brain development and modulate
behavior and cognition in animals through gut-brain connections, and research
in humans suggests that it may be a modulating factor in many disorders. This
study reports findings from a shotgun metagenomic analysis of the oropharyngeal
microbiome in 16 individuals with schizophrenia and 16 controls. High-level
differences were evident at both the phylum and genus levels, with Proteobacteria,
Firmicutes, Bacteroidetes, and Actinobacteria dominating both schizophrenia
patients and controls, and Ascomycota being more abundant in schizophrenia
patients than controls. Controls were richer in species but less even in their
distributions, i.e., dominated by fewer species, as opposed to schizophrenia patients.
Lactic acid bacteria were relatively more abundant in schizophrenia, including
species of Lactobacilli and Bifidobacterium, which have been shown to modulate
chronic inflammation. We also found Eubacterium halii, a lactate-utilizing species.
Functionally, the microbiome of schizophrenia patients was characterized by an
increased number of metabolic pathways related to metabolite transport systems
including siderophores, glutamate, and vitamin B12. In contrast, carbohydrate and
lipid pathways and energy metabolism were abundant in controls. These findings
suggest that the oropharyngeal microbiome in individuals with schizophrenia is
significantly different compared to controls, and that particular microbial species
and metabolic pathways differentiate both groups. Confirmation of these findings in
larger and more diverse samples, e.g., gut microbiome, will contribute to elucidating
potential links between schizophrenia and the human microbiota.
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INTRODUCTION
Schizophrenia is a serious neuropsychiatric disorder with substantial social and economic
consequences such as low performance on social knowledge and emotion recognition, high family burden, and high annual treatment costs worldwide, especially in
treatment-resistant subjects (Achim et al., 2013; Kennedy et al., 2014; Knapp, Mangalore
& Simon, 2004). Population-based studies suggest that the risk of an individual developing
schizophrenia is based on both genetic and environmental factors (van Os, Kenis &
Rutten, 2010); e.g., concordance-rates between monozygotic twins are higher than those
between dizygotic twins, and adopted children of schizophrenic parents have similar risks
of schizophrenia to those of their biological parents (Fowler et al., 2012; Tienari et al.,
1985). Additionally, a recent genome-wide association study examining a large cohort
of subjects (36,989 cases and 113,075 controls) found 108 independent associated loci
that appeared to account for 7% of a given person’s risk of developing schizophrenia,
as assessed by polygenic risk scores. Moreover, some of the key loci were related to host
immunity, thus providing genetic support for immune dysregulation in schizophrenia
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Likewise, a
population-based study has identified that single-nucleotide polymorphisms associated
with schizophrenia are also associated with immunity (Andreassen et al., 2014), which
has also been confirmed in clinical/epidemiological studies (Benros et al., 2014; Eaton
et al., 2010). More studies linking immunity/immune disorders and schizophrenia have
been published (reviewed in Severance et al., 2013); however, the source of the immune
activation in most individuals has not been identified.
Recent advances in High-Throughput Sequencing (HTS) technologies have enabled
the study of unculturable/difficult to culture microbial communities and have shown that
the human body harbors microbial ecosystems that interact with human physiological
processes, thus influencing health and disease (Cho & Blaser, 2012; De Vos & De Vos, 2012;
Pflughoeft & Versalovic, 2012). The collection of genes and genomes belonging to these
microbial communities, the microbiome, has been studied using HTS to demonstrate the
extent to which the human microbiota plays a role in human health issues ranging from
obesity to respiratory disease (Huang, 2013; Turnbaugh et al., 2006).
In relation to human health, observational and experimental studies have shown
that the microbiome can modulate the immune response and its alterations could
be associated with disease (reviewed in Round & Mazmanian, 2009). For instance, a
recent experimental study using an osteomyelitis mice model has shown that diet can
modulate the microbiome (high fat diet induces a decrease in Prevotella), which in turn
offered protection against inflammatory bone disease (Lukens et al., 2014). Increasing
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evidence suggests that alteration of the microbiota not only has effects on intestinal
conditions such as Crohn’s and other Inflammatory Bowel Diseases (Gevers et al., 2014;
Morgan et al., 2012), but also in the development of systemic immune diseases such as
rheumatoid arthritis (Scher & Abramson, 2011; Wu et al., 2010), type I diabetes (Kriegel et
al., 2011; Suez et al., 2014), and allergic diseases (Castro-Nallar et al., in press; Hong et al.,
2010; Nakayama et al., 2011; Pérez-Losada et al., 2015).
Although the mechanisms by which microorganisms outside the brain might impact
the central nervous system (CNS) are not known, the human microbiota have been
demonstrated to affect brain development and to modulate cognition through imbalances
in the microbiota-gut-CNS axis (reviewed in Clarke et al., 2012; Davari, Talaei & Alaei,
2013; Foster & McVey Neufeld, 2013; Hsiao et al., 2013). As a consequence, microbiota
alterations impact anxiety-like and depression-like behaviors and have been linked to
neurodevelopmental disorders such as autism spectrum disorder (Kang et al., 2013) and
multiple sclerosis (Farrokhi et al., 2013; Yokote et al., 2008).
While there is growing evidence suggesting a key role for the human microbiome in
mental health, the microbiome of schizophrenia patients has not yet been extensively
explored (reviewed in Dinan, Borre & Cryan, 2014; Severance, Yolken & Eaton, 2014;
Yolken & Dickerson, 2014). Recent work by our group has shown that the oropharyngeal
“phageome” of individuals with schizophrenia differs from that of non-schizophrenic
controls. In particular, Lactobacillus phage phiadh was significantly more abundant in
schizophrenia individuals when controlling for age, gender, race, socioeconomic status,
or cigarette smoking (Yolken et al., 2015). However, studies evaluating the structure
and diversity of bacterial and fungal communities in schizophrenia individuals are not
available. In particular, gut and oral microbiome analysis could provide insights into
the identity and quantity of the microbes residing in these body sites, and whether they
encode functions that are relevant to and/or known to be involved in schizophrenia. In
addition, the analysis of the oral microbiome could prove instrumental in the development
of taxonomic and functional biomarkers because of the ease of sampling, which can be
performed in a non-traumatic manner, allowing to distinguish schizophrenia patients
from healthy individuals, as it has been done in other illnesses (e.g., Farrokhi et al., 2013).
The premise of our study is that the oropharyngeal microbiome may be associated with
or contribute to an altered immune state consistent with findings in schizophrenia; hence,
differences in the microbiome could be instrumental to pinpoint associations between
microbial diversity and immune response. Consequently, here we aim to characterize
the schizophrenia microbiome by interrogating the oropharyngeal microbiome structure
regarding its taxonomic and functional diversity. This represents a second crucial step
towards understanding the relationship between microbiome diversity and schizophrenia.
Our initial study identified differences in the oropharyngeal phageome; whereas here we
focus on the complete microbiome (virus, bacteria, fungi). Future work will investigate
additional microbiome compartmentalizations, including gut, and amniotic fluid.
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MATERIALS AND METHODS
Samples and sequencing
Participants were individuals with schizophrenia and non-psychiatric controls from
the Stanley Research Program at Sheppard Pratt Hospital who were enrolled in the
period between January 1, 2008 and March 1, 2012 in a study of the association
between antibodies to infectious agents and serious mental illness. The methods for
identification and recruitment of individuals with schizophrenia and controls have been
previously described (Dickerson et al., 2013). Briefly, individuals with schizophrenia were
recruited from psychiatric treatment programs at a large psychiatric health system and
community psychiatric programs in central Maryland. Inclusion criteria were: a diagnosis
of Schizophrenia or Schizoaffective disorders (established by consensus of the research
team based on the SCID for DSM-IV Axis 1 Disorders—Patient Edition and available
medical records). Participants met the following additional criteria: age 18–65; proficient
in English; absence of any history of intravenous substance abuse; absence of mental
retardation; absence of HIV infection; absence of serious medical disorder that would
affect cognitive functioning; absence of a primary diagnosis of alcohol or substance use
disorder (First et al., 2012). In order to define an individual with schizophrenia, we used
the criteria from the DSM IV manual of the American Psychiatric Association (2000). The
Institutional Review Boards of Sheppard Pratt Hospital and the Johns Hopkins School of
Medicine approved this study. Informed consent was obtained from all participants prior
to enrollment into the study (Protocols SMRI/SPHS: 2002-01 and SF/SPHS: 2000-02).
We selected the oropharynx microbiome since it is easily accessible by non-invasive
techniques and biological samples from cases and controls could be collected and
processed in an identical manner. Moreover, studies have found the oral microbiome to be
associated with immune and neurological diseases such as inflammatory bowel disease and
Alzheimer’s disease, and offers opportunities for development of taxonomic and functional
biomarkers (Docktor et al., 2012; Farrokhi et al., 2013; Shoemark & Allen, 2014).
Throat swabs were obtained at the study visit (16 individuals with schizophrenia and 16
controls) by research staff that rubbed a sterile cotton swab at the back of subjects’ throat
and then immediately put the swab into a sterile container. The swabs were either sent
immediately to the processing laboratory or refrigerated and then sent to the processing
laboratory in a refrigerated container. Throat swabs were kept frozen at −70 ◦ C until
further processing. DNA was extracted from throat swabs using Qiagen’s Gentra Puregene
Buccal Cell Kit. The collection brush heads from the swab ends were excised and incubated
at 65 ◦ C overnight in the kit cell lysis solution. Aliquots of 75–100 ng of DNA were used
to generate sequencing libraries using the Nugen Ultralow DR Multiplex System following
the manufacturer’s instructions. Briefly, following sonication, the DNA fragments were
end repaired and ligated to barcoded adaptors. Using the adaptors as PCR priming sites,
the library was amplified using 15 cycles of amplification. The samples were purified
by chromatography and analyzed by capillary electrophoresis in a Bioanalyzer 2100 to
confirm size and concentration. Sequencing libraries were matched one case and one
control per lane and anonymized until analysis. Samples were sequenced at the same time
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to further minimize batch effects. Sequences were generated using the Illumina HiSeq
2000 platform producing approximately 58-million single-end reads of 100 nucleotides in
length per sample (File S1). All sequence data were deposited in the Sequence Read Archive
and are available under the BioProject PRJNA255439.

Sequence read preprocessing
Reads were preprocessed using PRINSEQ-lite 0.20.4 (trimming reads and bases <25
PHRED, removing exact duplicates, and reads with undetermined bases). We constructed
a ‘target’ genome library containing all bacterial, fungal, and viral sequences from the
Human Microbiome Project Reference Database (http://www.hmpdacc.org/reference
genomes/reference genomes.php; 131 archeal, 326 lower eukaryotes, 3,683 viral, 1,751
bacterial species) using the PathoLib module from PathoScope 2.0 (Hong et al., 2014). We
aligned the reads to these libraries using the Bowtie2 algorithm (Langmead & Salzberg,
2012), and then filtered any reads that also aligned to the human genome (hg19) as
implemented in PathoMap (—very-sensitive-local -k 100—score-min L,20,1.0). We then
applied PathoScope 2.0—specifically the PathoID module (Francis et al., 2013)—to obtain
accurate read counts for downstream analysis.

Statistical analyses
Exploratory and differential species abundance analyses were performed in R 3.1.2 and
Bioconductor 3.0 (Gentleman et al., 2004) using packages xlsx 0.5.7, gtools 3.4.1, CHNOSZ
1.0.3.1, plyr 1.8.1, ggplot2 1.0.0, reshape2 1.4.1, gplots 2.16.0, Phyloseq 1.10.0, and DESeq2
1.6.3 (Love, Huber & Anders, 2014; McMurdie & Holmes, 2013; Wickham, 2009). Briefly,
various indices (Richness: Observed, Chao1, ACE; richness and evenness: Shannon,
Simpson, Inverse Simpson, Fisher’s alpha) were obtained using the plot richness function
of the PhyloSeq package and beta diversity was obtained using R base package. We used
richness indices to estimate the number of species in the microbiome with (Chao1;
ACE) (Chao, 1984; Colwell & Coddington, 1994) and without (Observed) correction for
subsampling. In addition, we used metrics that aim to measure diversity by accounting
for “evenness” or homogeneity (Shannon; Fisher; Simpson; InvSimpson) (Jost, 2007). For
instance, communities dominated by one species will exhibit low evenness, as opposed to
communities where species are relatively well represented (high evenness).
For statistical comparison between cases and controls, the number of mapped reads
estimated in PathoScope was normalized across all samples using the variance stabilized
transformation method as implemented in DESeq2 using a generalized linear model
(Love, Huber & Anders, 2014). Then, statistical inference was performed using the negative
binomial Wald test (with Cook’s distance to control for outliers (Cook, 1977)) and adjusted
by applying the Benjamini–Hochberg method to correct for multiple hypotheses testing
(Benjamini & Hochberg, 1995) at an alpha value =0.01. We controlled for covariates by
adding them as coefficients in DESeq’s linear model.
We also used generalized linear models implemented in STAMP and MaAsLin (Morgan
et al., 2012; Parks et al., 2014) to test for differences between groups. In STAMP, differences
in relative abundance between two groups of samples were compared using White’s
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non-parametric t test (White, Nagarajan & Pop, 2009). We estimated confidence intervals
using a percentile bootstrapping method (10,000 replications), and false discovery rate
(FDR) in multiple testing was controlled by the Storey’s FDR at 0.05 (Storey, Taylor &
Siegmund, 2004). MaAsLin is a multivariate statistical framework that finds associations
between clinical metadata and microbial community abundance. These associations are
without the influence of the other metadata in the study. In our study, we used MaAsLin to
detect the effect of schizophrenia (presence/absence) in microbiome species composition
taking into account the effects of other variables (confounders) in the study population
(medication, smoker, age, gender and race).
Descriptive statistics were run on all samples. Cases and controls were compared with
respect to demographic and substance use variables; χ y tests were used for categorical
variables and t tests were used for continuous variables. Principal coordinate analysis
(PCoA) was performed on a Jensen–Shannon distance matrix derived from read counts
aggregated by genus as estimated in PathoScope.
In order to explore and formally test for differences in the coding potential of
the oropharyngeal microbiome, non-human reads were mapped against the Kyoto
Encyclopedia of Genes and Genomes (Kanehisa & Goto, 2000) (KEGG; from June 2011;
1291309 genes with KO assignments) database using a two-stage local alignment algorithm
as implemented in UBLAST (e-value 1e−9 ), part of the USEARCH package v7.0.1090
(Edgar, 2010). Then, metabolic pathway abundance and coverage was estimated using the
Human Microbiome Project metabolic reconstruction pipeline, HUMAnN v0.99, where
pathways are inferred as gene sets using maximum parsimony as the optimality criterion
[MinPath (Ye & Doak, 2009)] and smoothed-averaged over all genes within a pathway.
Significant differences between groups were tested using Kruskal–Wallis rank sum and
Wilcoxon tests (alpha = 0.05) using Linear Discriminant Analysis as implemented in LEfSe
(Segata et al., 2011). All figures were plotted using the ggplot2 and PhyloSeq packages.

RESULTS
Study sample demographic variables
The study sample consisted of 16 schizophrenia patients and 16 controls. Participants
had a mean age of 34.5 years, were 56.3% male, and 37.5% white. On average, their
mothers had over 13 years of education, and 31.3% of participants smoked. Cases were
more likely to be cigarette smokers than controls (χ 2 = 18.6; p value < 0.0001; 62.5%
and 0%, respectively) and were also more likely to have a higher body mass index (BMI;
controls = 25.5, cases = 34.7; p value < 0.0001). Groups did not differ significantly on
demographic variables such as maternal education, self-reported race, age, or gender
(Table 1).

Microbial communities in the oropharynx of schizophrenia
patients differ significantly from those in controls
At the phylum level, schizophrenia samples exhibit higher proportions of Firmicutes
across samples in comparison to controls, where we observe higher relative proportions
of Bacteroidetes and Actinobacteria (Fig. 1). Relative proportions of other phyla such as
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Table 1 Study samples’ demographics data. Cases and controls were matched and not statistically
different with the exception of smoking condition and body mass index.

Age
Male gender
White race
Mother’s education
Cigarette smoker
Body Mass Index

Entire sample
(N = 32)

Controls
(N = 16)

Schizophrenia
cases (nonsmoking; N = 6)

Schizophrenia
cases
(all; N = 16)

34.5 ± 7.8
18/32 (56.3%)
12/20 (37.5%)
13.6 ± 2.9
10/32 (31.3%)
30.1 ± 7.0

34.3 ± 10.1
9/16 (56.3%)
5/16 (31.3%)
14.1 ± 3.0
0/16 (0%)
25.5 ± 4.5

35.9 ± 3.4
3/6 (50%)
4/6 (66.6%)
14 ± 3.4
0/0 (0%)
33.4 ± 7.5

34.7 ± 4.8
9/16 (56.3%)
7/16 (43.8%)
13.1 ± 2.97
10/16 (62.5%)
34.7 ± 6.0

schizophrenia

control

OTUs
Actinomyces odontolyticus

1.00

Relative Proportion of Mapped Reads

Atopobium parvulum
Rothia dentocariosa
Rothia mucilaginosa
Actinobacteria (other)
Prevotella melaninogenica

0.75

Bacteroidetes (other)
Streptococcus gordonii
Streptococcus mitis
Streptococcus oralis
Streptococcus pneumoniae
Streptococcus salivarius

0.50

Streptococcus sp. oral taxon 071
Veillonella parvula
Veillonella sp. 3_1_44
Veillonella sp. 6_1_27
Firmicutes (other)
Fusobacterium periodonticum

0.25

Fusobacteria (other)
Campylobacter concisus
Delftia acidovorans
Neisseria flavescens
Neisseria subflava
Proteobacteria (other)

0.00

*********

ES_069t
ES_088t
ES_089t
ES_095t
ES_099t
ES_104t
ES_106t
ES_107t
ES_110t
ES_114t
ES_158t
ES_207t
ES_208t
ES_209t
ES_210t
ES_211t

ES_001t
ES_007t
ES_010t
ES_014t
ES_017t
ES_019t
ES_024t
ES_043t
ES_046t
ES_048t
ES_080t
ES_108t
ES_116t
ES_132t
ES_137t
ES_147t

rare (other)

*
Samples

Figure 1 Oropharyngeal microbial composition at phylum and species levels exhibits different patterns for schizophrenia and control samples. The stacked bar chart shows the most prevalent species
present in schizophrenia and controls color-coded by phylum. Green, Actinobacteria; Orange, Bacteroidetes; Blue, Firmicutes; Green, Proteobacteria. The symbol (*) indicates samples from smoker
individuals.

Fusobacteria and Proteobacteria do not differ greatly (Fig. 1). Overall, groups do not differ
significantly at the phylum level, which is also supported by non-metric multidimensional
scaling (Fig. S1B; NMDS; Bray–Curtis dissimilarity). Differences between smoker and
non-smoker cases are not evident at the phylum level (Fig. 1; smoker cases denoted with a
star).
Regarding species diversity among samples, we observe that controls are richer in the
number of species compared to schizophrenia samples. The median number of observed
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species is higher than the interquartile range of schizophrenia samples, which is congruent
with other richness metrics (Chao1, ACE, and Fisher; Fig. S1A), suggesting that controls
contain a higher number of lower abundance species as opposed to schizophrenia samples.
However, we observe that species abundance in controls is dominated by fewer species
(Streptococcus spp.; Fig. 1), as evidenced by their lower evenness or homogeneity (Simpson,
and Inverse Simpson; Fig. S1A), although both groups are fairly equivalent in species
richness when accounting for species evenness (Shannon; Fig. S1A). Chao1 index provides
an estimate of the expected number of species in a habitat. We found that the observed
richness is similar to Chao1 richness, suggesting that we are capturing most of the diversity
present in the samples (Fig. S1A).

Microbial species commonly inhabiting the oropharynx are
differentially more abundant in schizophrenia patients than in
controls
Out of a total of 25 differentially abundant species (bacteria and fungi), we found
6 microbial species to be more abundant in cases than controls after accounting for
different library sizes, smoking condition and medication (covariates were added as extra
coefficients; Wald test; p value < 0.01). Overall, schizophrenia samples were relatively
more abundant for Lactic Acid Bacteria (LAB) including Lactobacillus and Bifidobacterium.
Of these, the largest effect was observed in Lactobacillus gasseri, which appeared to be at
least 400 times more abundant in schizophrenia patients than controls (log2 = 8.4 ± 1.2
standard error). We also detected Eubacterium halii, a lactate-utilizing bacterium present
in human feces, and Candida dubliniensis, which is an opportunistic fungus that is part of
the oral fungal microbiome (Table 2).
Using STAMP, we also found Streptococcus gordonii, Streptococcus thermophilus, and
Streptococcus sp. (oral taxon 071) to be relatively more abundant in schizophrenia. The
latter species was also detected by MaAsLin, which in addition detected Bifidobacterium
pseudocatenulatum, Bifidobacterium breve (File S3).
We also identified species that were related to variables other than schizophrenia/nonpsychiatric controls. Among these, we found that some species were related to individuals’ age (Neisseria subflava, Neisseria flavescens, Neisseria polysaccharea, Escherichia
fergusonii, and Pseudomonas protegens), being white (Klebsiella variicola, Actinomyces
phage Av-1, Streptococcus sp. (oral taxon 071)), and to cigarette smoking (Streptococcus
mitis, Streptococcus pneumoniae) (File S3). Regarding species relatively more abundant
in cases, we found that these preferentially belonged to Pasteurella, Neisseriaceae, and
Flavobacteriaceae. We also collated the list of species found in schizophrenia patients
against a list of potential contaminants published by Salter et al. (2014) and found no
obvious contaminants (Table 2).
We also tested whether microbial composition could differentiate schizophrenia
patients from controls by inferring synthetic variables that could explain the variability
of the samples at the genus level (PCoA on Jensen–Shannon distance; Fig. 2). We observe
that schizophrenia samples tend to group together (first three coordinates = 40%, 25%
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Table 2 Microbial species relatively more abundant in schizophrenia samples than in controls. Effect size represents the size of the difference
of schizophrenia samples over controls. The effect size as an associated standard error, and multiple comparisons were adjusted using the
Benjamini–Hochberg procedure (BH).
Effect size
(log2 fold
change)

Effect size
standard
error

p value
(BH
adjusted)

Phylum

Genus

Species

Description

8.37

1.17

2.55E−10

Firmicutes

Lactobacillus

Lactobacillus gasseri

6.81

0.99

9.61E−10

Firmicutes

Catenibacterium

4.82

0.99

3.94E−05

Firmicutes

Eubacterium

Catenibacterium
mitsuokai
Eubacterium hallii*

5.71

1.29

3.13E−04

Ascomycota

Candida

Candida dubliniensis

2.98

0.80

4.17E−03

Firmicutes

Lactobacillus

Lactobacillus
salivarius

3.79

1.06

6.30E−03

Actinobacteria

Bifidobacterium

Bifidobacterium
pseudocatenulatum

Lactic acid bacterium. Member of diverse
communities including gut, vaginal, and
oral microbiome. Appears to be the main
species of Lactobacilli that inhabits the
human gastrointestinal tract
Phylogenetic relative of Lactobacilli. Found
in gastrointestinal tract
Butyrate forming, Lactate-utilizing bacterium. Present in human feces
Opportunistic fungus. Part of the oral
fungal microbiome. Present in periodontal
disease
Lactic acid bacterium. Member of diverse
communities including vaginal and oral
microbiome
Lactic acid bacterium. Gastrointestinal
tract, vagina and mouth of mammals,
including humans

Notes.
* indicates that Eubacterium hallii has been associated with smoking in the nasopharynx microbiome (PMID: 21188149).

and 23% of variance, respectively); however, this differentiation seems to be influenced by
mental health status and in part by cigarette smoking (Figs. 2A and 2B).

Microbial metabolic pathways differ between schizophrenics and
controls
We identified 18 metabolic pathways enriched and 14 decreased in schizophrenia (p
value < 0.05; Fig. 3). Pathways significantly associated with schizophrenia were related
to environmental information processing, in particular to transport systems such as
saccharide, polyol, and lipid transport systems (M00197, M00194, M00200), peptide
and nickel transport (M00239), metallic cation, iron-siderophore, and vitamin B12
transport (M00246), and phosphate and amino acid transport (M00222), including
glutamate transport (M00233). In turn, pathways found in control individuals, but not in
individuals with schizophrenia, were related to energy metabolism, such as ATP synthesis
and ATP synthase (M00144, M00150, M00157, M00164) and carbohydrate and lipid
metabolism, such as central carbohydrate metabolism (M00011, M00009, M00007) and
lipopolysaccharide metabolism (M00060).

DISCUSSION
This study is among the first surveys on the composition and differences in the microbiome
of schizophrenia patients and healthy controls using shotgun metagenomic sequencing.
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A

B

0.6

Principal Coordinate 3 (23%
(22% of variance)

Principal Coordinate 2 (25% of variance)

0.6
0.6

0.4
0.4

0.2
0.2

0.0
0.0

0.3

Status

Status

Schizophrenia

Schizophrenia

Control
0.0

Control

Cigarrette Smoking

Cigarrette Smoking

No

No

Yes

Yes

−0.3

−0.2
−0.2

−0.4
−0.4

−0.50
−0.50

−0.25

0.00 −0.25

0.25

0.50

−0.6

0.00

−0.50
−0.50

−0.25 −0.25
0.25

0.00

0.00 0.25

0.50
0.25 0.50

0.50

Principal Coordinate 1 (40% ofPrincipal
variance)Coordinate 1 (40%
Principal
Coordinate
Coordinate
1 (40%1of
(40%
variance)
of variance)
ofPrincipal
variance)

Figure 2 Covariation of community structure shows that diversity patterns of samples correlate
with disease status, i.e., schizophrenia and controls, and potentially with smoking (at the genus
level). Points represent principal coordinate analysis (PCoA loadings) on Jensen–Shannon Diversity
distances. Principal coordinates 1 and 2 in (A) (65% of variance) and principal coordinates 1 and 3
in (B) (63% of variance).
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Figure 3 Microbial metabolic pathways with significantly altered abundances in the schizophrenia
oropharyngeal microbiome. MXXXXX codes correspond to KEGG modules, i.e., a collection of manually defined functional units (genes). LDA, linear discriminant analysis.

The oropharyngeal microbiome is particularly attractive for microbiome-associated
biomarker development because biological samples can be collected and processed in an
identical and non-traumatic manner from both individuals with psychiatric disorders and
controls. Additionally, while oral and gut microbiomes share little taxonomic resemblance,
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both are significantly associated (Ding & Schloss, 2014), which might be instrumental for
future diagnostic aids. In addition, shifts in oral microbiome diversity have been linked to
immune and neurological diseases such as inflammatory bowel disease and Alzheimer’s
disease (Docktor et al., 2012; Shoemark & Allen, 2014). Although there is little mechanistic
understanding about the role of the microbiome on inflammatory and neurological
disease, some studies have found specific markers (microbes and metabolites) associated
with both gut and oral microbiomes. These markers have been shown to enter the systemic
circulation and elicit systemic immune responses, thus serving as specific biomarkers of
disease (Clark et al., 2013; Farrokhi et al., 2013).
We show that the oropharynx microbiome in schizophrenics is significantly different in
comparison from that of healthy controls. High-level differences were evident at both the
phylum and genus levels; however, the overall composition of the microbiome is similar to
those previously reported (Belda-Ferre et al., 2011; Dewhirst et al., 2010). Proteobacteria,
Firmicutes, Bacteroidetes, and Actinobacteria dominated both schizophrenia patients and
controls, with Ascomycota being more abundant in schizophrenia patients than controls.
At the genus level, we identified key members of the healthy oropharynx microbiome
such as Prevotella, Capnocytophaga, Campylobacter, Veillonella, Streptococcus, Neisseria and
Haemophilus; as reported in other studies that characterize the oropharynx microbiome
(Charlson et al., 2010). We also detected in schizophrenia samples an increase in lactic acid
bacteria, Candida, and Eubacterium, and a marked reduction of Neisseria, Haemophilus,
and Capnocytophaga, suggesting a characteristic dysbiosis signature (Gao et al., 2014).
Notably, decreases in Neisseria and Capnocytophaga abundance have been associated with
cigarette smoking (Charlson et al., 2010); therefore, although we incorporate cigarette
smoking as a coefficient in our models, we can not rule out that this observation is due
to smoking and not mental health status. We also found that Streptococcus mitis and
Streptococcus pneumoniae abundance was associated with smoking, which is consistent
with other findings from culture independent (Charlson et al., 2010) and culture-based
studies (Brook & Gober, 2005).
Reagent and laboratory contamination in genomics in general (Merchant, Wood &
Salzberg, 2014; Strong et al., 2014) and in microbiome studies in particular (Lusk, 2014;
Salter et al., 2014; Weiss et al., 2014) have been recently brought into attention as an
alarming problem. Although contamination affects primarily samples coming from low
diversity ecosystems, in our analysis we used high statistical significance (p value < 0.01
coupled with independent filtering and outlier removal) to prevent spurious detection
of contaminants as differentially abundant. Moreover, our laboratory protocols (library
preparations; sequencing) were performed simultaneously for all samples, and both case
and control samples were loaded in the same sequencing lane, thus minimizing chances of
contamination, i.e., contamination correlated with disease status.
Some of the most abundant species found in samples from individuals with schizophrenia (e.g., Lactobacillus, Bifidobacterium, Candida) have been reported previously as
members of the respiratory tract microbiome and have been linked to opportunistic
infections (Kim & Sudbery, 2011; Land et al., 2005). However, relatively abundant species
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in schizophrenia samples are not exclusive inhabitants of the respiratory tract, as bacterial
species we detected have also been described in the gastrointestinal tract (Dillon, 1998;
Duncan, Louis & Flint, 2004; Kageyama & Benno, 2000). In addition, some reports show
that oral and intestinal Lactobacilli share a common origin in the oral cavity (Dal Bello &
Hertel, 2006), suggesting that species such as L. salivarius and L. gasseri (both identified
in this study) might be allochthonous to the human gut and autochthonous to the
respiratory tract (Reuter, 2001), and therefore potentially useful for microbiome signature
development (Aagaard et al., 2012; Haberman et al., 2014). In addition, Lactobacilli
(except L. salivarius) in the intestine has been linked to emotional behavior regulation and
alteration of mRNA expression patterns of the GABA receptor via the vagus nerve (Bravo
et al., 2011). Lactobacilli have also been linked to chronic inflammation and anxiety-like
behavior (Bercik et al., 2010). In particular, L. gasseri has been shown to modulate the
immune system by altering the function of dendritic cells, enterocytes, and components of
innate immunity (Luongo et al., 2013; Selle & Klaenhammer, 2013).
We also detected non-bacterial species such as fungi and DNA viruses (phage;
File S2) that would have been beyond the scope of gene marker surveys, e.g., 16S rRNA
gene (Weinstock, 2012). One fungal species, Candida dubliniensis, was differentially
abundant in individuals with schizophrenia, which has been associated to immunecompromised individuals (Eggimann & Pittet, 2014; Sebti et al., 2001), but also found
in healthy respiratory tract microbiomes (prevalence of 75% Candida) (Ghannoum et
al., 2010). This suggests that the high abundance of these microbes in schizophrenia
individuals might be associated with altered immune responses or changes in the local
environment that enable their outgrowth, as observed in other diseases (Bisgaard et al.,
2007; Molyneaux et al., 2013). We also detected viruses, primarily phages, in our datasets;
however our group has published a more comprehensive characterization of them in a
larger study population (see Yolken et al., 2015).
We also assessed the functional diversity of the oropharynx microbiome in schizophrenia and control samples. There is little information regarding the functional diversity of the
respiratory tract in general, and a complete lack of information in schizophrenia. In our
study, we identified metabolic pathways significantly associated with the microbiomes
of schizophrenics (i.e., environmental information processing) including glutamate
transport (M00233), while the microbiomes of healthy controls were enriched for
bioenergy pathways. Microbial metabolic pathways found in schizophrenia samples have
also been described in samples from the respiratory and digestive tracts such as in gingiva,
oral cavity, and stool (M00239, M00276, M00200, M0028, M0029), reinforcing the notion
that oral and gut microbial communities share features and are associated (Meehan &
Beiko, 2012; Sczesnak et al., 2011; Seekatz et al., 2014; Segata et al., 2012). Dominant
hypotheses for the pathophysiology of schizophrenia, as well as recent genetic studies,
point to neurotransmitter disturbances in glutamatergic and dopaminergic activities
(Falkai, Schmitt & Cannon, 2011; Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014). While we found glutamate related pathways to be more abundant in
schizophrenia samples, the design and scope of this study does not allow us to evaluate
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mechanistic hypotheses regarding pathophysiology of schizophrenia and the potential
contribution of the microbiome. Study designs based on metatransciptomics or dual
RNAseq strategies coupled with advanced statistical techniques such as feature reduction
might be instrumental to detect associations between known host genetic determinants
and their expression, and microbiota structure (Morgan et al., 2015). Undoubtedly, study
designs using larger sample sizes and both RNA and DNA information (Franzosa et al.,
2014) collected from different body sites (e.g., intestines) are needed for accurate statistical
validation of microbial and metabolic as promising biomarkers for schizophrenia. Further
analyses of other body sites involving larger study populations will be presented elsewhere
as we collect relevant samples.
In summary, by using metagenomic sequencing, we have shown that it is possible to distinguish schizophrenia patients from controls by profiling the oropharyngeal microbiome
based on the diversity and composition of microbes. Additionally, microbiomes from
schizophrenics and controls differ in the functions they potentially encode suggesting it
may be important to further characterize other body sites such as the intestines. These
differences could be exploited for the development of biomarkers and ultimately for
therapeutic interventions.
The fact that all controls were non-smokers, although statistically accounted for in
our inferences, might confound the effects of schizophrenia from those of smoking on
microbiome composition. A recent study found no significant differences in diversity
(alpha and beta) between the oral microbiome in healthy smokers and non-smokers
without psychiatric disorders (Morris et al., 2013). However, this and other studies have
found specific taxa (Haemophilus influenzae, Streptococcus pneumoniae, Megasphaera and
Veillonella spp) to be differentially abundant in smokers and non-smokers (in humans
Charlson et al., 2010; in mice Voss et al., 2015). Here we found that the distributions of two
Streptococcus species were better explained by whether the individual was a smoker than
whether the individual had schizophrenia.
Additionally, studies in animal models have indicated that changes in the microbiome
can cause alterations in behavior and cognitive functioning and that these changes can be
modulated by probiotic and antibiotic interventions (Jakobsson et al., 2010; Martin et al.,
2008). The establishment of a link between the microbiome and behavioral and cognitive
functioning in humans might lead to the development of new strategies for the prevention,
management, and treatment of psychiatric disorders.
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